Kisspeptin-10 dosage: reported doses and schedule
A short-acting experimental peptide that triggers reproductive hormone release.
Also called: KP-10, KP10, Kisspeptin 112-121, Metastin 45-54, NSC 741805.
Reproductive axis peptides · KISS1 receptor agonist.
Typical reported dose: 100–200 mcg once a day
- Single IV pulse: 0.24 nmol/kg IV once one bolus, into a vein. Studied in a trial. Studied in: 13 healthy adult men. (source)
- IV dose-finding arms: 0.01, 0.03, 0.1, 0.3, 1 or 3 mcg/kg IV once one bolus per separate visit, into a vein. Studied in a trial. Studied in: Healthy men; n=6 for boluses and n=4 in each infusion experiment. (source)
- 22.5-hour IV infusion: 3 mcg/kg IV bolus; 90 minutes later, 4 mcg/kg/h IV for 22.5 hours continuous infusion per hour, into a vein. Studied in a trial. Studied in: Healthy men; n=6 for boluses and n=4 in each infusion experiment. (source)
- 9-hour IV infusion: 1.5 mcg/kg/h IV for 9 hours continuous infusion per hour, into a vein. Studied in a trial. Studied in: Healthy men; n=6 for boluses and n=4 in each infusion experiment. (source)
- IV bolus arms by sex: Men: 0.3, 1, 3 or 10 nmol/kg. Follicular women: 1, 3 or 10; preovulatory women: 10 nmol/kg. one bolus per study visit, into a vein. Studied in a trial. Studied in: 11 healthy men and 35 healthy women; 4–5 per dose group. (source)
- Single SC dose-finding arms: 2, 4, 8, 16 or 32 nmol/kg SC once one bolus per study visit, under the skin. Studied in a trial. Studied in: Healthy women in the follicular phase. (source)
These are doses reported in labels, trials or user reports, not a personal plan. Check the source behind each one.
Related to Kisspeptin-10
- Gonadorelin: A short-acting fertility hormone used in tests and specialist pump therapy.
- hCG: A fertility hormone with limited testosterone add-on evidence and no proven weight-loss benefit.
- Bremelanotide: An as-needed injection for low libido before menopause; nausea is common.
- Hexarelin: A peptide that releases growth hormone; repeated use can weaken the response.
Sources
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2026
- Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act, FDA · FDA · 2026
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks, FDA · FDA · 2026
- Concerns regarding the public health risks associated with unapproved peptide products, Therapeutic Goods Administration and Chief Medical Officer · Therapeutic Goods Administration · 2026
- Medicines, European Medicines Agency · European Medicines Agency · 2026
- The 2026 Prohibited List, World Anti-Doping Agency · WADA · 2026
- Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026, Australian Government · Australian Government · 2026
- Supply unlicensed medicinal products (specials), MHRA · 2025
- October 29, 2024 Meeting of the Pharmacy Compounding Advisory Committee
- October 29, 2024 Pharmacy Compounding Advisory Committee (PCAC) Meeting
- Unauthorized injectable peptide drugs seized from Optimum Wellness Centre in Calgary, Alberta may pose serious health risks, Health Canada
- Chronic subcutaneous kisspeptin-10 stimulates gonadotropin secretion for 12 days in healthy men., Yeung AC et al. · European journal of endocrinology · 2026
- Dynamic modulation of LH secretion by continuous kisspeptin infusion in healthy men., Naveed A et al. · Hormones (Athens, Greece) · 2026
- Intravenous kisspeptin 112-121 bolus does not acutely impact circulating vasopressin in humans., Galbiati F et al. · Journal of neuroendocrinology · 2026
- Intranasal kisspeptin administration rapidly stimulates gonadotropin release in humans., Mills EG et al. · EBioMedicine · 2025
Sources checked: 2026-10-18.
Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.